Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Home uterine activity monitors

This article was originally published in The Gray Sheet

Executive Summary

HUAMs for detection of preterm labor should be downclassified from Class III to Class II, FDA tentatively concludes in a July 30 Federal Register notice. The agency says it agrees with the recommendations put forth during an October 1997 meeting of its Obstetrics and Gynecology Devices Panel, which was convened to respond to a petition seeking downclassification of the devices submitted to FDA by Corometrics Medical Systems (1"The Gray Sheet" Oct. 13, 1997, p. 11). Following its review of public comments, the agency plans to approve or deny the petition via a letter to Corometrics. In a separate July 30 Federal Register notice, FDA issues a revised draft guidance document with advice on premarket submissions for HUAMs. The document is identical to an earlier draft of the guidance (2"The Gray Sheet" May 31, In Brief), except for a recommendation on the type of information that should be stored in HUAM patient registries
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT012118

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel